(Updated - August 7, 2023 10:12 AM EDT)

Stifel analyst Paul Matteis downgraded Sage Therapeutics (NASDAQ: SAGE) from Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

Oppenheimer Reiterates Perform Rating on Sage Therapeutics (SAGE)August 7, 2023 4:56 PM Form S-8 Sage Therapeutics, Inc. August 7, 2023 7:49 AM Wedbush Downgrades Sage Therapeutics (SAGE) to NeutralAugust 7, 2023 7:23 AM Form 10-Q Sage Therapeutics, Inc. For: Jun 30August 7, 2023 7:21 AM SAGE Therapeutics (SAGE) sinks nearly 50% as trading resumes following CRLAugust 7, 2023 7:12 AM Sage, Biogen receive setback despite FDA approval of postpartum depression drug. This is whyAugust 7, 2023 7:04 AM SAGE Therapeutics (SAGE) to resume trading at 7:10AM ETAugust 7, 2023 6:47 AM Form 8-K Sage Therapeutics, Inc. For: Aug 07August 7, 2023 6:46 AM SAGE Therapeutics (SAGE) Misses Q2 EPS by 13cAugust 7, 2023 6:44 AM Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business ProgressAugust 7, 2023 6:30 AM SAGE Therapeutics (SAGE), Biogen (BIIB) ZURZUVAETM approved in PPD, receives CRL for MDDAugust 7, 2023 6:24 AM RBC Capital Downgrades Sage Therapeutics (SAGE) to Sector PerformAugust 7, 2023 3:10 AM Oppenheimer Downgrades Sage Therapeutics (SAGE) to PerformAugust 7, 2023 2:22 AM Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023August 4, 2023 10:45 PM FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive DisorderAugust 4, 2023 10:42 PM